Literature DB >> 29597075

Bionanotechnology for vaccine design.

Steven Frey1, Ana Castro1, Ammar Arsiwala1, Ravi S Kane2.   

Abstract

There have been significant advances in the design of nanostructured scaffolds for eliciting robust immune responses. One method to produce strong immune responses is to emulate the appearance of a pathogen. Since pathogens such as viruses and bacteria often display multiple copies of ligands on their surfaces, the immune system is particularly sensitive towards multivalent displays of antigens. Consequently, when designing a vaccine, it is advantageous to decorate a nanostructured surface with multiple copies of an antigen. This review highlights the design and efficacy of a diverse set of recently developed nanostructured vaccine scaffolds.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29597075      PMCID: PMC6082679          DOI: 10.1016/j.copbio.2018.03.003

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  45 in total

1.  Haloarchaeal gas vesicle nanoparticles displaying Salmonella antigens as a novel approach to vaccine development.

Authors:  P DasSarma; V D Negi; A Balakrishnan; J-M Kim; R Karan; D Chakravortty; S DasSarma
Journal:  Procedia Vaccinol       Date:  2015

2.  Single-walled carbon nanotubes as delivery vehicles enhance the immunoprotective effects of a recombinant vaccine against Aeromonas hydrophila.

Authors:  Yu-Xin Gong; Bin Zhu; Guang-Lu Liu; Lei Liu; Fei Ling; Gao-Xue Wang; Xin-Gang Xu
Journal:  Fish Shellfish Immunol       Date:  2014-11-14       Impact factor: 4.581

3.  Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose.

Authors:  Jasdave S Chahal; Omar F Khan; Christopher L Cooper; Justine S McPartlan; Jonathan K Tsosie; Lucas D Tilley; Saima M Sidik; Sebastian Lourido; Robert Langer; Sina Bavari; Hidde L Ploegh; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-05       Impact factor: 11.205

4.  Immunogenicity and protective potential of a Plasmodium spp. enolase peptide displayed on archaeal gas vesicle nanoparticles.

Authors:  Sneha Dutta; Priya DasSarma; Shiladitya DasSarma; Gotam K Jarori
Journal:  Malar J       Date:  2015-10-14       Impact factor: 2.979

5.  Novel platform technology for modular mucosal vaccine that protects against streptococcus.

Authors:  Mehfuz Zaman; Victoria Ozberk; Emma L Langshaw; Virginia McPhun; Jessica L Powell; Zachary N Phillips; Mei Fong Ho; Ainslie Calcutt; Michael R Batzloff; Istvan Toth; Geoffrey R Hill; Manisha Pandey; Michael F Good
Journal:  Sci Rep       Date:  2016-12-15       Impact factor: 4.379

6.  A polymer/oil based nanovaccine as a single-dose immunization approach.

Authors:  Sara Vicente; Belen Diaz-Freitas; Mercedes Peleteiro; Alejandro Sanchez; David W Pascual; Africa Gonzalez-Fernandez; Maria J Alonso
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

7.  Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity.

Authors:  Kwinten Sliepen; Gabriel Ozorowski; Judith A Burger; Thijs van Montfort; Melissa Stunnenberg; Celia LaBranche; David C Montefiori; John P Moore; Andrew B Ward; Rogier W Sanders
Journal:  Retrovirology       Date:  2015-09-26       Impact factor: 4.602

8.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

9.  Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination against Leishmania Infection.

Authors:  Anna Paula V Moura; Luiza C B Santos; Carlos Ramon Nascimento Brito; Edward Valencia; Caroline Junqueira; Adalberto A P Filho; Mauricio R V Sant'Anna; Nelder F Gontijo; Daniella C Bartholomeu; Ricardo T Fujiwara; Ricardo T Gazzinelli; Craig S McKay; Carlos A Sanhueza; M G Finn; Alexandre Ferreira Marques
Journal:  ACS Cent Sci       Date:  2017-09-13       Impact factor: 14.553

Review 10.  Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development.

Authors:  William A Rodríguez-Limas; Karthik Sekar; Keith E J Tyo
Journal:  Curr Opin Biotechnol       Date:  2013-03-05       Impact factor: 9.740

View more
  5 in total

Review 1.  Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.

Authors:  Donella M Beckwith; Maré Cudic
Journal:  Semin Immunol       Date:  2020-01-09       Impact factor: 11.130

2.  Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer.

Authors:  Cassandra E Callmann; Lisa E Cole; Caroline D Kusmierz; Ziyin Huang; Dai Horiuchi; Chad A Mirkin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

3.  Rational vaccinology with spherical nucleic acids.

Authors:  Shuya Wang; Lei Qin; Gokay Yamankurt; Kacper Skakuj; Ziyin Huang; Peng-Cheng Chen; Donye Dominguez; Andrew Lee; Bin Zhang; Chad A Mirkin
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-08       Impact factor: 11.205

4.  Unimicellar hyperstars as multi-antigen cancer nanovaccines displaying clustered epitopes of immunostimulating peptides.

Authors:  Hamilton Kakwere; Elizabeth S Ingham; Riley Allen; Lisa M Mahakian; Sarah M Tam; Hua Zhang; Matthew T Silvestrini; Jamal S Lewis; Katherine W Ferrara
Journal:  Biomater Sci       Date:  2018-09-19       Impact factor: 6.843

5.  MVsim is a toolset for quantifying and designing multivalent interactions.

Authors:  Bence Bruncsics; Wesley J Errington; Casim A Sarkar
Journal:  Nat Commun       Date:  2022-09-06       Impact factor: 17.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.